 |
|
|
| |
Influence of the HCV Protease Inhibitor
Boceprevir on the Pharmacokinetics of the HIV Integrase Inhibitor Raltegravir
|
| |
| |
Reported by Jules Levin
19th Conference on Retroviruses and Opportunistic Infections (CROI)
Seattle, WA
March 6, 2012
Clara T.M.M. de Kanter1,2, Maren I. Blonk1,2, Angela P.H. Colbers1,2, Quirine Fillekes1,2, Bas J.J.W. Schouwenberg3, David M. Burger1,2 1Department of Pharmacy, 2Nijmegen Institute for Infection, Inflammation and Immunity (N4i), 3Department of Pharmacology and Toxicology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
|
| |
|
|
|
|
|
